Combined surgery enables better graft fixation

Article

A stable IOL, decreased pseudophacodonesis and improved graft fixation are the benefits of combining Descemet membrane endothelial keratoplasty with glued intrascleral haptic fixation of a posterior-chamber IOL in patients with aphakic or pseudophakic bullous keratopathy, according to recently published research.

A stable IOL, decreased pseudophacodonesis and improved graft fixation are the benefits of combining Descemet membrane endothelial keratoplasty with glued intrascleral haptic fixation of a posterior-chamber IOL in patients with aphakic or pseudophakic bullous keratopathy, according to recently published research.

The researchers base their conclusions on a study of 6 patients who had corneal decompensation and inadequate capsular support requiring implantation/exchange of an IOL; all underwent the single-staged procedure at a tertiary care centre. The investigators injected air during surgery to judge the stability of the anterior chamber and structure of the iris diaphragm–IOL complex. They performed iridoplasties in two of the patients. They observed patients after surgery.

Regarding other complications, 1 patient had a partial graft detachment that had to be re-bubbled, and 1 patient had a small peripheral detachment that spontaneously resolved. The graft remained attached in all patients.

Visual acuity (VA) improved in all patients and corrected distance VA significantly changed following surgery. Mean preoperative corrected distance VA was 0.11 ± 0.07, and mean postoperative corrected distance VA was 0.7 ± 0.17.

The mean postoperative endothelial cell density at 6 months was 1710.3 ± 205.8 cells/mm2.

To read the abstract of the study, go to the Journal of Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.